AIkido Pharma (NASDAQ:AIKI) Shares Pass Above 200 Day Moving Average of $2.23

Shares of AIkido Pharma Inc. (NASDAQ:AIKI) passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $2.23 and traded as high as $3.00. AIkido Pharma shares last traded at $2.93, with a volume of 20,966 shares traded.

AIkido Pharma Trading Up 2.8 %

The company has a market cap of $16.07 million, a price-to-earnings ratio of -0.76 and a beta of 0.93. The stock has a 50 day moving average price of $2.29 and a two-hundred day moving average price of $2.23.

Institutional Investors Weigh In On AIkido Pharma

A number of institutional investors and hedge funds have recently modified their holdings of the company. Jane Street Group LLC increased its position in AIkido Pharma by 247.4% during the first quarter. Jane Street Group LLC now owns 100,096 shares of the business services provider’s stock worth $45,000 after acquiring an additional 71,284 shares during the period. Two Sigma Advisers LP boosted its position in AIkido Pharma by 630.0% in the third quarter. Two Sigma Advisers LP now owns 86,700 shares of the business services provider’s stock valued at $593,000 after buying an additional 74,824 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of AIkido Pharma by 26.5% during the third quarter. Dimensional Fund Advisors LP now owns 57,849 shares of the business services provider’s stock valued at $396,000 after purchasing an additional 12,111 shares in the last quarter. Finally, Two Sigma Investments LP acquired a new stake in shares of AIkido Pharma in the third quarter valued at about $367,000. 10.88% of the stock is owned by institutional investors.

AIkido Pharma Company Profile

AIkido Pharma Inc, a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.